APA (7th ed.) Citation

De Laurentiis, M., Mazza, M., Mansutti, M., Masetti, R., Ballatore, Z., Torrisi, R., . . . Zamagni, C. (2019). 335P - Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study. Annals of Oncology, 30, v119. https://doi.org/10.1093/annonc/mdz242.030

Chicago Style (17th ed.) Citation

De Laurentiis, M., et al. "335P - Safety and Efficacy of Ribociclib (RIBO) + Letrozole (LET) in Patients (pts) with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor 2-negative (HER2–) Advanced Breast Cancer (ABC): Interim Results from the Italian Cohort of the CompLEEment-1 (C-1) Study." Annals of Oncology 30 (2019): v119. https://doi.org/10.1093/annonc/mdz242.030.

MLA (9th ed.) Citation

De Laurentiis, M., et al. "335P - Safety and Efficacy of Ribociclib (RIBO) + Letrozole (LET) in Patients (pts) with Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor 2-negative (HER2–) Advanced Breast Cancer (ABC): Interim Results from the Italian Cohort of the CompLEEment-1 (C-1) Study." Annals of Oncology, vol. 30, 2019, p. v119, https://doi.org/10.1093/annonc/mdz242.030.